Most Read Articles
06 Dec 2018
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.

Early response to dexamethasone implant predicts visual outcomes in DME

07 Nov 2017

In diabetic macular oedema (DME), visual outcomes following intravitreal dexamethasone implant therapy may be predicted by early treatment response, according to a study. Specifically, eyes with optimal early responses demonstrate better outcomes compared with eyes having suboptimal early visual acuity gains.

With the aim of determining whether early visual acuity response to dexamethasone implant in DME was associated with long-term outcome, researchers reviewed the clinical data of 102 eyes with DME treated with intravitreal dexamethasone implant. Eyes with vitroretinal interface abnormalities or that underwent vitrectomy were excluded.

Eyes were grouped into three according to the change in best-corrected visual acuity (BCVA) at 3 months: logMAR equivalence of <5-letter, 5 to 9-letter or ≥10-letter gain. Assessments included visual acuity outcomes and the association between early (3 months) and overall change in BCVA.

Of the eyes, 44.1 percent showed <5-letter, 18.6 percent had 5 to 9-letter and 37.3 percent had ≥10-letter BCVA improvements at 3 months. Significantly more eyes in the robust (≥10-letter) early response group achieved ≥10-letter gains at study conclusion than in the suboptimal (<5-letter) early response group (29 vs 6.7 percent; p=0.009).

Regression analysis found that change in BCVA at 3 months positively correlated with overall change in BCVA (p=0.002).

Researchers pointed out that an adjustment to therapy or alternative options such as pars plana vitrectomy with inner limiting membrane peeling may be considered for DME patients with poor early response, which is associated with worse outcomes compared with robust early response.

Further work must be done to clarify which alterations to the treatment regimen will most benefit DME patients with poor early response, as well as to characterize and understand the underlying factors that lead some patients to respond more favourably to particular treatments so that therapies can be tailored individually, researchers said.

Editor's Recommendations
Most Read Articles
06 Dec 2018
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.